Asa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.
Sylvia Asa, MD, PhD, FRCPC, FCAP, pathologist, Toronto General Hospital/Research Institute, professor, University of Toronto, discusses the ambiguity of certain subtypes of thyroid cancer. Asa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.
Asa says researchers are finding different mutations that make these different subtypes what they are. Some of these subtypes include TERT promoter mutations, as well as epigenetic changes such as alterations in the micro RNAs and epigenetic activation or silencing of genes. She says uncovering more information about these mutations and changes could aid in the creation of different therapies.
Guideline Spotlights Early-Line Agents for GEP-NETs
November 29th 2023New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens
November 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.
Read More